Repligen (RGEN) PT Lowered to $190 at JPMorgan, 'All in, we applaud RGEN’s consistent performance during the bioprocessing recovery'
Tweet Send to a Friend
JPMorgan analyst Rachel Vatnsdal lowered the price target on Repligen (NASDAQ: RGEN) to $190.00 (from $200.00) while maintaining a Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
